[
  {
    "ts": null,
    "headline": "Analyst Highlights ‘Game Changer’ Catalyst for Eli Lilly (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, Capital Wealth Planning founder and CIO, said that he agrees with the call and thinks the company’s GLP-1 oral medication Orforglipron could […]",
    "url": "https://finnhub.io/api/news?id=3ea17e31f7f44d2830604ae3a7685fce1044f6ecde84dd438364288616d7d451",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753733543,
      "headline": "Analyst Highlights ‘Game Changer’ Catalyst for Eli Lilly (LLY)",
      "id": 136113337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, Capital Wealth Planning founder and CIO, said that he agrees with the call and thinks the company’s GLP-1 oral medication Orforglipron could […]",
      "url": "https://finnhub.io/api/news?id=3ea17e31f7f44d2830604ae3a7685fce1044f6ecde84dd438364288616d7d451"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
    "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
    "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720800,
      "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
      "id": 136108043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
      "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248"
    }
  },
  {
    "ts": null,
    "headline": "Ireland's 'economic miracle' at risk from tariffs",
    "summary": "The deal between the United States and the European Union may have averted a transatlantic trade war, but worries persist in Ireland where crucial sectors are dependent on US multinationals.But \"higher tariffs than there have been\" will make transatlantic trade \"more expensive and more challenging,\" he added.",
    "url": "https://finnhub.io/api/news?id=911af6025161aa2888b29fa639255f8fa1f429694cfeff1a6653765f0e3232ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753719141,
      "headline": "Ireland's 'economic miracle' at risk from tariffs",
      "id": 136107800,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The deal between the United States and the European Union may have averted a transatlantic trade war, but worries persist in Ireland where crucial sectors are dependent on US multinationals.But \"higher tariffs than there have been\" will make transatlantic trade \"more expensive and more challenging,\" he added.",
      "url": "https://finnhub.io/api/news?id=911af6025161aa2888b29fa639255f8fa1f429694cfeff1a6653765f0e3232ed"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Gears Up to Report Q2 Earnings: Here's What to Expect",
    "summary": "Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.",
    "url": "https://finnhub.io/api/news?id=ae60b02c0449d28f4fff96c21b0e1eebd1c463a0d29e887217f207d5b258b2a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753712640,
      "headline": "Biogen Gears Up to Report Q2 Earnings: Here's What to Expect",
      "id": 136107934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.",
      "url": "https://finnhub.io/api/news?id=ae60b02c0449d28f4fff96c21b0e1eebd1c463a0d29e887217f207d5b258b2a4"
    }
  },
  {
    "ts": null,
    "headline": "This is the Most Dangerous Week for Investors in 20 Years",
    "summary": "This might be the most critical week for investors in years. In fact, in over two decades of investing, and more than a decade as a professional analyst, I’ve never seen a single week with this many potentially market-moving headlines. Between earnings surprises, critical inflation and jobs data, a Federal Reserve decision, and a looming […]",
    "url": "https://finnhub.io/api/news?id=3315ac2616db1af65296df57dceb135172d67259603dcb2c9d1869e150750af9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753711725,
      "headline": "This is the Most Dangerous Week for Investors in 20 Years",
      "id": 136107935,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "This might be the most critical week for investors in years. In fact, in over two decades of investing, and more than a decade as a professional analyst, I’ve never seen a single week with this many potentially market-moving headlines. Between earnings surprises, critical inflation and jobs data, a Federal Reserve decision, and a looming […]",
      "url": "https://finnhub.io/api/news?id=3315ac2616db1af65296df57dceb135172d67259603dcb2c9d1869e150750af9"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban",
    "summary": "LONDON (Reuters) -A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market confidence, investors and analysts say.  New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called compounded versions of Wegovy took effect, amounting to 181,200 in the week ended July 18, according to data from IQVIA that was shared with Reuters by industry analysts.  Total Wegovy prescriptions have also increased, narrowing the lead for Eli Lilly and Co's Zepbound.",
    "url": "https://finnhub.io/api/news?id=f3be02f95a064a660c79eded7cfe8ca85f0d3f7ee21a1001a4347b7b33ca7532",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753697057,
      "headline": "Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban",
      "id": 136107936,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LONDON (Reuters) -A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market confidence, investors and analysts say.  New Wegovy prescriptions have increased by about 33% since May 22, when a U.S. Food and Drug Administration ban on so-called compounded versions of Wegovy took effect, amounting to 181,200 in the week ended July 18, according to data from IQVIA that was shared with Reuters by industry analysts.  Total Wegovy prescriptions have also increased, narrowing the lead for Eli Lilly and Co's Zepbound.",
      "url": "https://finnhub.io/api/news?id=f3be02f95a064a660c79eded7cfe8ca85f0d3f7ee21a1001a4347b7b33ca7532"
    }
  },
  {
    "ts": null,
    "headline": "Blockbuster Drugs on Patent Cliffs Research Report 2025 | 2030 Patent Cliff to Be Largest Since 2010, Hitting Blockbusters Like Keytruda, Eliquis, and Darzalex",
    "summary": "Upcoming 2025-2030 patent cliff threatens revenue for major pharma companies as Merck, BMS, and J&J top drugs lose exclusivity. Strategies like M&A, R&D investment, and life cycle management could help sustain growth. Companies like Eli Lilly showcase resilience with a 165% projected revenue boost.Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The \"Blockbuster Drugs on Patent Cliffs\" report has been added to ResearchAndMarkets.com's offering. This report talks about the effect of patent cliffs on blo",
    "url": "https://finnhub.io/api/news?id=5f0ab869d43ff0466ffdd37ff5a622d27778906a5712a9437d57d7affe83531b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753689660,
      "headline": "Blockbuster Drugs on Patent Cliffs Research Report 2025 | 2030 Patent Cliff to Be Largest Since 2010, Hitting Blockbusters Like Keytruda, Eliquis, and Darzalex",
      "id": 136107937,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Upcoming 2025-2030 patent cliff threatens revenue for major pharma companies as Merck, BMS, and J&J top drugs lose exclusivity. Strategies like M&A, R&D investment, and life cycle management could help sustain growth. Companies like Eli Lilly showcase resilience with a 165% projected revenue boost.Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The \"Blockbuster Drugs on Patent Cliffs\" report has been added to ResearchAndMarkets.com's offering. This report talks about the effect of patent cliffs on blo",
      "url": "https://finnhub.io/api/news?id=5f0ab869d43ff0466ffdd37ff5a622d27778906a5712a9437d57d7affe83531b"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Remains Bullish on Eli Lilly (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Eli Lilly and Company (NYSE:LLY), raising the target price from $1,133 to $1,135. On July 9, Eli Lilly and Company (NYSE:LLY) announced that the US […]",
    "url": "https://finnhub.io/api/news?id=6246cbba4b9cf984f3c79a3dff46a851e556e459e6aad6353bde01516dec5b21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682879,
      "headline": "Morgan Stanley Remains Bullish on Eli Lilly (LLY)",
      "id": 136107938,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the top low volatility healthcare stocks to buy now. On July 10, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Eli Lilly and Company (NYSE:LLY), raising the target price from $1,133 to $1,135. On July 9, Eli Lilly and Company (NYSE:LLY) announced that the US […]",
      "url": "https://finnhub.io/api/news?id=6246cbba4b9cf984f3c79a3dff46a851e556e459e6aad6353bde01516dec5b21"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, Guggenheim reiterated its Buy rating on Eli Lilly & Company (NYSE:LLY) ahead of the company’s second-quarter earnings report and increased its price target from $936 to $942. In contrast to the consensus predictions of $4.39 […]",
    "url": "https://finnhub.io/api/news?id=84a7e5e918208320900d011de5089518ca2da0bb149ccef3e5a7c28b4714fa78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753681315,
      "headline": "Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales",
      "id": 136107939,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, Guggenheim reiterated its Buy rating on Eli Lilly & Company (NYSE:LLY) ahead of the company’s second-quarter earnings report and increased its price target from $936 to $942. In contrast to the consensus predictions of $4.39 […]",
      "url": "https://finnhub.io/api/news?id=84a7e5e918208320900d011de5089518ca2da0bb149ccef3e5a7c28b4714fa78"
    }
  }
]